Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OVID vs PYPD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Captures Overall Composite Edge (31.1 SELL vs 52.3 HOLD), While OVID Leads 3–2 on Growth & Valuation Pillars

PYPD Overall Winner 6-Pillar Tally: OVID 3 – 2 PYPD (1 Tie) Matrix Metrics: OVID 5 – 4 PYPD

As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Ovid Therapeutics Inc. (OVID) on higher Unified Composite conviction (31.1/100 SELL vs. 52.3/100 HOLD) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while OVID wins 3–2 across the 6-pillar growth and valuation breakdown. OVID trades at $2.27 (1.8x Forward P/E, -4693.7% operating margin) versus PYPD at $6.43 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While OVID currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4693.7% operating margin) and revenue trajectory (+0.0% vs. -88.3% YoY).
  • Technical & Structure Timing Caution: OVID is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OVID vs PYPD
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.27
-5.62% 1D
Market Cap $479.4M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.04β · 99% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 29.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $2.51 · SMA50: $2.49
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40

6-Pillar Scorecard Institutional Category Breakdown (OVID 3 – 2 PYPD)

Columns: Metric · OVID · PYPD
1. Valuation Multiples OVID
Forward P/E 1.8x N/M
Trailing P/E 1.8x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale OVID
Revenue Growth (YoY) -88.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.5M N/A
Market Cap $479.4M $132.2M
3. Profitability & Quality OVID
Gross Margin 100.0% N/A
Operating Margin -4693.7% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -35.4% -243.6%
4. Balance Sheet & Cash Flow PYPD
Cash Generation (TTM) -$58M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.5M Net Cash $5.0M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 131.0% (30th %ile) 106.3% (12th %ile)
Put/Call OI Skew 0.06x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OVID (5) vs PYPD (4)
Institutional Metric OVID PYPD Criterion Row Edge
Market Capitalization
Scale
$479.4M $132.2M Larger Scale OVID
Trailing P/E Ratio
Valuation
1.8x N/M Lower Multiple OVID
Forward P/E Ratio
Valuation
1.8x N/M Lower Multiple OVID
Revenue Growth (YoY)
Growth
-88.3% +0.0% Higher Growth PYPD
Operating Margin (TTM)
Profitability
-4693.7% 0.0% Higher Margin PYPD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-35.4% -243.6% Higher ROE OVID
52-Week Range Position
Momentum
56% ($1–$3) 80% ($4–$7) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
1.04β · 99% Vol 0.89β · 59% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
52.3 / 100 (HOLD) 31.1 / 100 (SELL) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$1.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M ($1.5M Net Cash) N/A ($5.0M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +27.48 pp
OVID: +4.38% · PYPD: +31.86%
3M Horizon PYPD +51.14 pp
OVID: -22.7% · PYPD: +28.44%
6M Horizon PYPD +40.81 pp
OVID: -5.62% · PYPD: +35.19%
1Y Horizon PYPD +5.69 pp
OVID: +73.56% · PYPD: +79.25%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OVID vs PYPD. Trailing 12-month operating profitability (OVID -4693.7% vs PYPD 0.0%) and valuation multiples (OVID 1.8x vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OVID ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin100.0%
Op. Margin-4693.7%
ROE / Fwd P/E-35.4% · 1.8x
PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OVID CONSOLIDATION
151d in phase · OBV DISTRIBUTION
Current IV 131.0%
IV Percentile 30th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $479.4M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OVID vs PYPD Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Ovid Therapeutics Inc. (OVID) on higher Unified Composite conviction (31.1/100 SELL vs. 52.3/100 HOLD) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while OVID wins 3–2 across the 6-pillar growth and valuation breakdown. OVID trades at $2.27 (1.8x Forward P/E, -4693.7% operating margin) versus PYPD at $6.43 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OVID currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4693.7% operating margin) and revenue trajectory (+0.0% vs. -88.3% YoY). Technical & Structure Timing Caution: OVID is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OVID leads the Growth & Scale pillar: OVID posts -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OVID generates $1.5M in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, OVID deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.

OVID screens cheaper on headline valuation multiples. OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OVID (-35.4% ROE) versus PYPD (-243.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 99% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.